Current stock page

Financial Data

HALO Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

HALOHalozyme Therapeutics, Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$100.27−$0.40 (−0.40%)

Latest quote

  • Momentum
    84
  • Value
    76
  • Quality
    81
  • Risk resilience
    63
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$492.97M$481M$376.71M$451.77M$354.26M$325.72M$264.86M$298.01M
Gross Profit$410.5M$401.83M$297.47M$373M$299.02M$279.36M$216.46M$255.95M
Operating Income$294.97M$287.65M$184.52M$240.7M$217.92M$202.44M$141.54M$175.5M
Net Income$247.05M$229.91M$150.05M-$141.59M$175.23M$165.16M$118.1M$137.01M
EPS$2.17$1.96$1.27-$1.2$1.49$1.36$0.96$1.08
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow$258.27M$240.89M$180.08M$219.03M$178.6M$99.71M$154.22M$178.47M
Capital Expenditure-$3.05M-$4.17M-$3.74M-$1.43M-$3.03M-$1.56M-$950K-$3.05M
Free Cash Flow$255.22M$236.72M$176.34M$217.6M$175.57M$98.15M$153.27M$175.42M
Net Cash Provided By Operating Activities$258.27M$240.89M$180.08M$219.03M$178.6M$99.71M$154.22M$178.47M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$3.47B$2.58B$2.67B$2.53B$2.22B$2.05B$2.2B$2.06B
Total Debt$3.25B$2.15B$2.14B$2.14B$1.51B$1.51B$1.51B$1.51B
Cash And Cash Equivalents$1.03B$163.14M$309.75M$133.82M$419.67M$61.86M$176.33M$115.85M
Total Liabilities$3.53B$2.43B$2.45B$2.48B$1.72B$1.72B$1.71B$1.7B
Total Stockholders Equity-$55.24M$143.54M$219.64M$48.81M$503.92M$332.75M$482.27M$363.82M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio26.1825.1323.3929.8914.1713.5515.4916.87
P/B ratio—72.4237.15194.0116.7522.6915.5920.6
P/S ratio6.33———————
Debt To Equity—14.959.7643.8934.543.134.14
Free Cash Flow Yield6.97%7.76%8.18%6.81%7.14%7.16%6.59%6.25%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio26.1825.1323.3929.8914.1713.5515.4916.87
P/B ratio—72.4237.15194.0116.7522.6915.5920.6
P/S ratio6.33———————
Return On Equity—288.13%158.83%6.49%118.17%167.48%100.64%122.06%
Debt To Equity—14.959.7643.8934.543.134.14

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe23.87x
Pb-206.56x
Revenue Growth Yoy39.15%
EPS Growth Yoy45.64%
Gross Margin82.27%
Operating Margin55.91%
ROE544.26%
ROIC22.61%
Debt To Equity-58.84
FCF Yield7.75%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$100.27
Volume2.28M
RSI (14)26.68
MACD-3.84
MACD signal-0.17
MACD histogram-3.67
ADX (14)40.24
SMA (50)$114.56
SMA (200)$85.43
ATR (14)$4.38
Historical volatility (annualized)60.95%
Volume (20-day average)2.36M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score63/100
Beta0.58
Annual volatility41.04%
Max Drawdown-24.13%
Sharpe Ratio0.95
VaR (95%, 1-day)-2.78%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

HALO Financial Data FAQ

What is Halozyme Therapeutics, Inc.'s revenue?

Halozyme Therapeutics, Inc.'s revenue is one of the core financial data points for HALO. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Halozyme Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Halozyme Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is HALO's EPS?

HALO's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Halozyme Therapeutics, Inc.'s net income?

Halozyme Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Halozyme Therapeutics, Inc. generate?

Free cash flow shows how much cash Halozyme Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Halozyme Therapeutics, Inc. have?

Cash and debt help frame HALO's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.